IRVINE, Calif., Feb. 29 /PRNewswire-FirstCall/ -- NuRx Pharmaceuticals Inc. (OTC Bulletin Board: NURX) today announced it has retained Russo Partners LLC for the provision of investor relations and corporate communications counsel.
The healthcare communications firm will implement a comprehensive program that consists of investor targeting, the scheduling of presentations at industry conferences, media relations and other corporate visibility initiatives. Russo Partners will collaborate with OTC Communications, a division of Rx Communications Group LLC, on the implementation of some program tactics.
"We are in a unique position with a clinical-stage pipeline and large portfolio of retinoid and rexinoid compounds that were developed over a number of years by world-class researchers who have joined the NuRx scientific team," said Harin Padma-Nathan, M.D., NuRx's president and CEO. "We intend to initiate three to four clinical trials this year. Therefore, the need to support the associated news flow prompted us to select Russo Partners to develop and lead our communications efforts with Wall Street and the biotech/pharmaceuticals community. The firm has the healthcare industry expertise, senior-level talent and investor and media relationships that were critical to our selection of a communications partner."
Russo Partners LLC, formerly Noonan Russo, provides strategic communications services to emerging healthcare - biotech, medical device, diagnostics and healthcare services - companies worldwide. Headquartered in New York City, the firm has a West Coast office in San Diego and an affiliated office in London. For more information, visit http://www.russopartnersllc.com.
NuRx Pharmaceuticals Inc. is an emerging biotech company focused on the
development of retinoid and rexinoid compounds with application in oncology
(treatment, prevention and adjunctive supportive therapy), t
|SOURCE NuRx Pharmaceuticals Inc.|
Copyright©2008 PR Newswire.
All rights reserved